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Disclaimer
The information within these guidelines is presented by the Centre 
for Palliative Care Research and Education (CPCRE) for the purpose of 
disseminating health information free of charge and for the benefit of 
the healthcare professional. 
While the CPCRE has exercised due care in ensuring the accuracy 
of the material contained within these guidelines, the document is 
a general guide only to appropriate practice, to be followed subject 
to the clinician’s judgement and the patient’s preference in each 
individual case.
 The CPCRE does not accept any liability for any injury, loss or damage 
incurred by use of or reliance on the information provided within 
these guidelines.
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Aims
These guidelines are intended to provide clinicians and palliative care services 
with guidelines to inform practice, the development of policy and procedures, 
and associated training and education programs in relation to portable 
subcutaneous infusion device (syringe driver) management.
Scope
Component One:
Literature Review & Development of Draft Clinical Practice Guidelines
A literature review was undertaken to identify the most current evidence 
regarding syringe driver management.  The following databases were 
searched for the purposes of these guidelines:  CINAHL, Medline, PsycArticles 
and PsycInfo.  The review of the literature was limited to adult patients and the 
English language, and covered a ten year period from 1995-2005.  Search terms 
included:  syringe drivers; subcutaneous infusions, end-of-life care, Graseby 
and palliative care.  An internet search using the Google search engine was 
also undertaken using the same search terms.  This identified relevant websites 
relating to syringe driver management.
The literature was rated for its level of evidence using the Joanna Briggs Levels 
of Evidence1 chart (Appendix A).  All abstracts identified during the search were 
assessed by two reviewers, and articles were retrieved for all papers that were 
identified by the project officer as being of relevance to the review topic.  
In addition, clinical notes, websites and books about syringe driver devices 
identified as relevant to the project were examined.  A total of 43 published 
and unpublished papers were considered for inclusion in the guidelines;  24 
were included.  A summary of the literature used to develop these guidelines 
is presented in Appendix B.
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Component Two:
Multidisciplinary Expert  Review of Draft Guidelines
An Expert Multidisciplinary Review Panel consisting of individuals working 
in relevant clinical areas was assembled.  Panel members included palliative 
care nurses, physicians and a pharmacist with expertise in palliative care 
medications.  The Multidisciplinary Review Panel was asked to review the 
evidence available and the draft guidelines and to provide feedback on their 
quality and relevance. The Review Panel also provided comments on the format 
for presenting, disseminating and promoting uptake of the guidelines.
Component Three:
Dissemination of Final Guidelines
The guidelines were prepared in two formats: A formal report providing a 
detailed summary of the evidence, and a summary card for wider distribution 
to clinicians. The guidelines were also made available on the CPCRE web site 
to enhance accessibility.
In addition, a workshop was held involving a cross section of professionals 
involved in the provision of palliative care.  The aim of the workshop was 
to raise awareness of the guidelines as well as to identify strategies for 
implementation. 
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Guidelines Summary
Section One: The patient experience
• Health care professionals should consider a syringe driver as a 
means of providing symptom control via subcutaneous infusion 
of drugs to treat unrelieved pain and other distressing symptoms 
when other routes are inappropriate or no longer effective2;
• Some patients may view the syringe driver as an invasion of their 
body privacy, and may perceive the device as an indicator of a 
poor prognosis3.
Section Two: Equipment guidelines and principles
• The most common syringe drivers in clinical use are the SIMS 
Graseby® MS16A and the MS263-5;
• The organisation’s protocol regarding the preparation and set-up 
for changing the device should always be used to guide practice;
• The syringe driver is normally used to deliver medications over a 24 
hour period to reduce the risk of errors in setting up the device3, 5-8;
• A 10 ml9 Luer-Lock® syringe, to prevent risk of disconnection6, should 
be used if volume/concentration permits; 20 and 30 ml syringes can 
be used, but may not fit as well9;
The same brand of syringe should be used each time to minimise 
errors in setting up the syringe driver and calculating the rate6, 9;
• The syringe should be measured every time the device is set up, as 
different brands of syringes have different diameters and lengths9;
• An aseptic technique should be used when preparing and setting 
up the infusion7;
• A  minimum volume extension set should be used to minimise 
dead-space in the line11;
•
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• When changing the extension set and/or cannula, prime the line 
after drawing up the prescribed medications to the appropriate 
length in the syringe2, 7-9, 11.  After priming the line, measure the  
syringe and document the line change and the time the syringe is 
calculated to finish;
• Teflon® or Vialon® cannulas are associated with less risk of site 
inflammation than metal butterfly needles8, 9, 11, 12.
Section Three: The selection, preparation and maintenance of the site
• General principles for appropriate site selection include: 
• Using an area with a good depth of subcutaneous fat;
• Using a site that is not near a joint;
• Selecting a site that is easily accessible such as the chest or 
the  abdomen.
• The longevity of the site can vary considerably from 1–14 days.  
Many variables influence the longevity of the site, such as the type 
of medication and type of cannula used;
• Select and use sites on a rotating basis2;
• When the tubing is placed against the skin, form a loop to prevent 
dislodgement if the tubing is accidentally pulled9.  Use a transparent, 
semi-occlusive dressing to cover the site, as this permits inspection 
of the site by the caregiver8, 9;
• Factors that cause site reactions include the tonicity of the 
medication, the pH of the solution, infection and prolonged 
presence of a foreign body12;  
• Site selection will be influenced by whether the patient is 
ambulatory, agitated and/or distressed;
• The chest or abdomen are the preferred sites6, specifically the 
upper, anterior chest wall above the breast, away from the axilla.  If 
the patient is cachectic, the abdomen is a preferred site6;
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Section Four: Drugs and diluents
• Syringe drivers can be used to deliver drugs to treat a variety of 
symptoms. Common symptoms include pain, nausea, vomiting,  
breathlessness, agitation, delirium and “noisy breathing”;
• A wide variety of drugs can be used together in different 
combinations with no clinical evidence of loss of efficacy13;  
• The more drugs that are mixed together, the greater the risk of 
precipitation and reduced efficacy9;  
•  2–3 drugs may be mixed in a syringe for a subcutaneous infusion 
(occasionally up to 4 drugs6, 10);  
•  If compatibility is an issue, the use of two syringe driver devices3 or 
regular or prn subcutaneous injection should be considered;
• Before mixing any drugs together in a subcutaneous infusion, check 
for stability information3, 6, 9 and check with hospital pharmacists;  
• Use of the boost facility is not recommended because it rarely 
provides enough analgesia to cover uncontrolled pain, and if 
other drugs are being infused, overdosing could occur of the 
other drug(s)6.   
• It is better to use breakthrough medication to treat uncontrolled 
symptoms than the boost facility14; 
• Normal saline is the most commonly used diluent in Australia15;
• The use of water for injection has been linked to pain due to 
its hypotonicity, although normal saline may be more likely to 
cause precipitation16;
• 5% dextrose is used only occasionally as a diluent6, and is less 
commonly used in Australia8.  
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Section Five: Patient/family education needs
• Patient and family education promotes safety and acceptance of 
the syringe driver as a means to providing improved symptom 
control12;
• Patient and family education includes:
• Explanation and education about what the device will do, 
and its advantages and possible disadvantages;
• Safety aspects;
• Ways to incorporate a subcutaneous infusion into their
 everyday life;
• Troubleshooting guidelines9.
Section Six: Patient assessment and troubleshooting guidelines
• When troubleshooting the equipment used in subcutaneous 
infusions, it is important to understand the normal functioning of 
the device9;
• Ensure that drug calculations are checked according to legislative 
requirements and organisational policy and protocols when the 
syringe driver is set-up17;
• Use only one type of syringe driver in each setting to prevent 
confusion which may lead to errors6, 8, 10, 18;
• Ensure that the organisational protocol is followed regarding 
priming of the line2, 6-9;
• Ensure that drugs being delivered are compatible3, 19;
• Ensure that a spare 9 volt battery is always available5, 6, 8;
• Thorough patient assessment is important when caring for patients 
with a subcutaneous infusion7, 12;
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Principles to include in patient assessment, recording and 
documentation include:
• Careful inspection of site, at least 4 hourly, for signs of inflammation 
and site reaction, and documentation of findings17;
• Careful inspection of syringe volume remaining6, at least 4 hourly, 
and documentation of findings;
• Asking the patient how they feel (or family member/carer, if the 
patient is unable to comprehend):  for example, are their pain and 
other symptoms controlled?;
• Documentation of symptom control and efficacy of interventions;
• Careful inspection of tubing for patency8, 9 at least 4 hourly and 
documentation of findings;
• Site inspection should be performed as part of routine care and 
includes principles such as checking for: tenderness at the site, 
presence of a haematoma and leaking at the insertion site3, 7, 9.
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Syringe Driver Guidelines
Background
 
Syringe drivers are defined as power driven devices that drive the plunger 
of a syringe at an accurately controlled rate to deliver medications10. Their 
use as a method of drug delivery to control symptoms in palliative care 
is a common and accepted practice. They provide symptom control via 
subcutaneous infusion of drugs to treat pain and other distressing symptoms 
when other routes are inappropriate or ineffective. However, their clinical use 
has evolved rather than being subject to close multiprofessional scrutiny and 
guideline formation20.
Many of the medications used in syringe drivers have narrow margins of 
error, so any errors that occur during prescription, preparation, administration 
and documentation of these infusions can result in adverse drug events and 
present an on-going risk for patient safety17.
There is evidence that such adverse incidents arise as a result of: 
• Errors in drug calculations20;
• Drug incompatibilities and instabilities20;
• Equipment failure (including disconnection)20; 
• Incorrect rates of infusion20;
• Inadequate user training9, 21;
• Inadequate documentation and record keeping20;
•  Poor servicing of equipment4, 9.  
The guidelines presented in this report have been developed in consultation 
with an Expert Multidisciplinary Review Panel in response to a lack of 
standardised information about syringe driver management in contemporary 
practice.  The guidelines are intended to avoid duplication of information and 
support primary care and specialist providers in palliative care who may not 
use such devices on a regular basis.
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The guidelines are presented in six sections:
• The patient experience;
• Commonly used equipment;
• The selection, preparation and maintenance of the site;
•  Drugs and diluents; 
• Patient/family education; and
• Patient assessment and troubleshooting guidelines.
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SECTION ONE
The patient experience
Although some studies report that subcutaneous infusions are well accepted 
and can achieve almost 100% compliance amongst people with life limiting 
illnesses12,  some people may view the device as an invasion of their body 
privacy, and may perceive the device as an indicator of a poor prognosis3. 
They may also restrict the person’s daily activities. 
Syringe drivers should be used when it is determined that improved symptom 
control will result from the continuous delivery of medication, and that other 
less invasive routes for administering medication are not possible2.  
Summary of the patient experience guidelines
• Health care professionals should consider a syringe driver as a means 
of providing symptom control via subcutaneous infusion of drugs to 
treat unrelieved pain and other distressing symptoms when other 
routes are inappropriate or no longer effective2;
• Some patients may view the syringe driver as an invasion of their 
body privacy, and may perceive the device as an indicator of a 
poor prognosis3.
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SECTION TWO
Equipment guidelines and principles
Summary Statement
• The most common syringe drivers in clinical use are the SIMS Graseby® 
MS16A and the MS263-5;
• The organisation’s protocol regarding the preparation and set-up for 
changing the device should always be used to guide practice;
•  The syringe driver is normally used to deliver medications over a 24 hr 
period to reduce the risk of errors in setting up the device3, 5-8;
• A 10 ml9 Luer-Lock®  syringe, to prevent risk of disconnection6, should be 
used if volume/concentration permits.  20 and 30 ml syringes can be used, 
but may not fit as well9;
• The same brand of syringe should be used each time to minimise errors 
in setting up the syringe driver and calculating the rate6, 9;
• The syringe should be measured every time the device is set up, as 
different brands of syringes have different diameters and lengths9;
• An aseptic technique should be used when preparing and setting up 
the infusion7;
• A  minimum volume extension set should be used to minimise dead-space 
in the line11;
• When changing the extension set and/or cannula, prime the line after 
drawing up the prescribed medications to the appropriate length in the 
syringe2, 7-9, 11.  After priming the line, measure the syringe and document 
the line change and the time the syringe is calculated to finish;
• Teflon or Vialon cannulas are associated with less risk of site inflammation 
than metal butterfly needles8, 9, 11, 12.
There are several types of syringe drivers available for use in palliative care.  It is 
important to verify the equipment that is used within the specific organisation, 
as all syringe drivers work quite differently.  The most common syringe drivers 
identified in clinical use in Queensland are the SIMS Graseby® MS16A and the 
MS26, which are electronic, battery driven syringe drivers.  This equipment is 
summarised in Table 1.  
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Management Principles
When setting up the equipment for a subcutaneous infusion, it is important 
to verify with the individual organisation’s protocol regarding the preparation 
and set-up for changing the device.   The management principles are the same 
for both the MS16A and the MS26 syringe drivers and include:
• The syringe driver should be used for the delivery of drugs over a 24 hour 
period, reducing the risk of errors in setting up the device;  
•  It is the length of the solution within the syringe—not the volume—that 
will determine the rate, i.e. the syringe driver delivery rate is a measure of 
distance, not a measure of volume administered;
• It is important to always measure the syringe prior to determining the rate 
each time the syringe driver is set up;
• A Luer-Lock® syringe6 is recommended to prevent accidental disconnection 
of the tubing from the syringe;
• 10 ml syringes are recommended unless there are drug concentration 
and/or volume issues.  A 10 ml syringe rests securely in the device, whereas 
a 30 ml syringe is more difficult to secure firmly onto the syringe driver;  
• Consider using a tamper-proof ‘lock-box’6 if there is a possibility of the 
patient or others tampering with the device, or using the boost facility. 
It is possible that a tamper-proof box is mandatory within an individual 
organisation as a risk management stipulation;
• Employ an aseptic technique when changing the device and resiting 
the cannula7;
• When changing the extension set and/or cannula, prime the line after 
drawing up the prescribed medications to the appropriate length in the 
syringe.  After priming the line, measure the syringe and document the line 
change and the time the syringe is calculated to finish;
• Ensure that the patient and the family have received a full explanation of 
how the syringe driver works, and its indications for use7. 
Regardless of which model Graseby® battery driven device is used, the size 
and brand of the syringe used is an important variable.  It is important to note 
that different brands of syringes have different diameters and lengths.  This 
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will impact upon the preparation of the medications used.  Therefore, care 
needs to be taken when considering syringe types, because each syringe may 
have a different barrel length for the same volume9, for example:
• Terumo® brand 10 ml syringe:  9.4 ml = stroke length of 48 mm;
• BD® brand 10 ml syringe:  7.8 ml = stroke length of 48 mm;
• Terumo® & BD® brand 20 ml syringe:  15 ml = stroke length of 48 mm;
• Terumo® brand 30 ml syringe:  20 ml = stroke length of 48 mm;
• BD® brand 30 ml syringe:  18 ml = stroke length of 48 mm.
The simplest way to overcome any error in relation to syringe type  is to measure 
the syringe against the scale on the syringe driver every time it is changed. 
Another important consideration when selecting syringe type is to ensure it is 
a Luer-Lock® syringe6, 12.  Luer-Lock® syringes are commonly recommended as 
they prevent accidental separation of the syringe from the infusion set10.  
A piece of equipment that should be considered is a tamper-proof box, or a 
‘lock-box’.  These lockable clear plastic covers have been devised to place over 
the driver to prevent accidental, or intentional, activation of the boost button 
or tampering with the rate control.  They should not be confused with the 
Perspex cover provided with the syringe driver. These covers simply provide 
protection for the device, but are not ‘tamper proof’.
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Management Guidelines
Table 1:  General principles and assembly of Graseby® syringe drivers
Graseby MS16A principles Graseby MS26 principles
Blue colour plate, delivers 
dose in mm/hr.
• Green colour plate, delivers 
dose in mm/24 hrs. 
•
To calculate rate take the 
length of the fluid in mm and 
divide it by the delivery time 
required in hours to arrive at 
a rate in mm/hr.  For example, 
48 mm of fluid divided by 24 
hours will equal a rate of 2 
mm per hour7.
• To calculate rate take the 
length of the fluid in mm and 
divide it by the delivery time 
in days to give the rate in 
mm/24 hours. For example, 
48 mm divided by one day 
equals 48 mm in 24 hours7.
•
Principles for both the MS16A and MS26
Measured in length per time rather than volume per time – in 
millimetres, not millilitres6, 7. 
•
Use of the boost facility is not advocated because it lacks a lock-out 
period.  If the boost is continually depressed, it will deliver 8 boluses 
before an alarm will sound.  In theory, this could occur until the 
syringe is empty, resulting in the patient being over-medicated, and a 
shortened infusion time9. 
•
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The boost dose rarely provides enough analgesia to cover uncontrolled 
pain, and if other drugs are being infused overdosing could occur 
of the other drug(s) concurrently.   It is better to use breakthrough 
medication to treat uncontrolled symptoms than the boost facility14.  
Breakthrough medication is defined as extra medication that may be 
required for symptoms that are not controlled by the medications 
prescribed for continuous delivery via the syringe driver.
•
Take care to identify the device that is being used to avoid calculation 
errors7, 9.  In 1994 the UK Department of Health issued a hazard 
warning about the possible confusion between the Graseby® MS16A 
and MS2618 syringe drivers.
•
The front panels of both drivers are similar, each having a length ruler, a 
start/test button,  rate setting dials and a flashing indicator.  Note:  there is 
no ‘off’ button, the battery needs to be removed to turn the driver off.  
•
Assembling the Graseby® syringe driver
The Graseby MS16A The Graseby MS26
Fill syringe with drugs prescribed, 
dilute to a maximum length of 
48 mm—use millimetre scale on 
the device as reference (Note that 
this is different to the MS26). 
Fill syringe with drugs prescribed, 
dilute to a maximum length of 
60 mm6—use millimetre scale on 
the device as reference (Note that 
this is different to the MS16A).
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Assembling the Graseby® syringe driver
The Graseby MS16A The Graseby MS26
Each time a new line is used, prime 
the line prior to the connection9.
Each time a new line is used, prime 
the line prior to the connection9.
Set delivery rate, obtained by 
dividing the length of the barrel 
by the required infusion time - 
calculated in hours.
Set delivery rate.   This is obtained 
by dividing the length of the 
barrel by the required infusion 
time - calculated in days. 
Connect syringe to driver by 
sliding the actuator up towards 
the plunger of the syringe by 
pressing and holding the button 
on the side.
Connect syringe to driver by 
sliding the actuator up towards 
the syringe plunger by pressing 
and holding the button on 
the side.  
Secure syringe into position using 
the rubber securing strap.
Secure syringe into position using 
the rubber securing strap.
Insert battery into device.  An 
audible alarm should sound.  This 
is the same sound heard if the 
infusion has ended, or the line 
is occluded.
Insert battery into the device.  An 
audible alarm should sound.  This 
is the same sound heard if the 
infusion has ended, or the line 
is occluded. 
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Assembling the Graseby® syringe driver
The Graseby MS16A The Graseby MS26
Pressing the ‘start’ button will 
silence the alarm, and activate 
the driver.  The green light on 
the driver should flash every 
second6,8.  If this doesn’t occur, 
the battery should be changed.  
The battery used is an alkaline 9V; 
each battery should deliver up to 
50 daily infusions6.
The green light will cease flashing 
approximately 24 hours before 
the battery is fully depleted6.
Pressing the ‘start’ button will 
silence the alarm, and activate 
the driver.  The green light on 
the driver should flash every 25 
seconds6, 8 – if this doesn’t occur, 
the battery should be changed.  
The battery used is an alkaline 9V; 
each battery should deliver up to 
50 daily infusions6.
The green light will cease flashing 
approximately 24 hours before 
the battery is fully depleted6.
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SECTION THREE
The selection, preparation and maintenance of the site 
Summary Statement
The selection, preparation and maintenance of the site:
• General principles for appropriate site selection include6: 
• Using an area with a good depth of subcutaneous fat;
• Using a site that is not near a joint;
• Selecting a site that is easily accessible—such as the chest or the 
abdomen;
• The longevity of the site can vary considerably from 1–14 days.  Many 
variables influence the longevity of the site, such as the type of medication 
and type of cannula/needle used;
• Select and use sites on a rotating basis2;
• When the tubing is placed against the skin, form a loop to prevent 
dislodgement if the tubing is accidentally pulled9.  Use a transparent, semi-
occlusive dressing to cover the site, as this permits inspection of the site by 
the caregiver8, 9;
• Factors that cause site reactions include: the tonicity of the medication, the 
pH of the solution, infection and prolonged presence of a foreign body12;  
• Site selection will be influenced by whether the patient is ambulatory, 
agitated and/or distressed;
• The chest or abdomen are the preferred sites6, specifically the upper, 
anterior chest wall above the breast, away from the axilla.  If the patient is 
cachectic, the abdomen is a preferred site6;
• The site should be inspected regularly.  Four hourly is recommended, or 
more frequently if indicated, to identify early and reduce the risk of site 
related complications;
• Site inspection should be performed as part of routine care and includes 
principles such as checking for:
• tenderness at the site; 
• presence of a haematoma and 
• leaking at the insertion site3, 7, 9.
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Site problems will cause the patient discomfort and may interfere with drug 
absorption, thus compromising effective symptom control.  The selection 
of an appropriate site for subcutaneous infusions via a syringe driver can 
help to avoid site problems, and minimise restrictions on the patient’s 
normal functioning.  
Site selection:
General principles for appropriate site selection include11:
• Use an area with good depth of subcutaneous fat;
• Use a site that is not near a joint;
• Select a site that is easily accessible such as the chest or abdomen.
Site selection will depend upon whether the patient is ambulatory, agitated 
and/or distressed.  The chest or abdomen is generally the preferred site6, 
specifically the upper, anterior chest wall above the breast, but away from the 
axilla11.  This site is preferred because it is easily accessible, rarely oedematous, 
and permits easy inspection by the caregiver11.  If the patient is cachectic, the 
abdomen may be a more appropriate site.  The upper arm can be used, but it 
makes it difficult for the patient to lie on their side and may lead to problems 
such as bruising6.  If the patient is distressed or agitated, using the area 
around the scapula may be useful to prevent dislodgement6, 9.   The insertion 
technique is summarised in Table 2.
Inappropriate site selection includes11:
• Lymphoedematous areas;
• Areas where there is broken skin;
• Skin sites that have recently been irradiated;
• Sites of infection;
• Bony prominences;
•  In close proximity to a joint;
• Sites of tumour;
• Skin folds;
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• Inflamed skin areas;
• Wherever ascites or pitting oedema are present;
• Where scarring is present;
• Areas where lymphatic drainage may be compromised2, for example in 
women who have had a mastectomy.
Reducing site irritation:
Many factors contribute to site reactions such as the tonicity of the medication, 
the pH of the solution, infection and prolonged presence of a foreign body12. 
Specific drugs used in palliative care that may cause site irritation include 
cyclizine6, 10, levomepromazine, methadone, promethazine, morphine tartrate 
and ketamine11.  Techniques that may be considered in consultation with the 
treating physician to minimise site irritation include: 
• Diluting the medications by using a larger syringe size6;
• Using normal saline (0.9%) if applicable, instead of water for injection6;
• Adding 1 mg of dexamethasone to the syringe9.  One Australian trial 
found that the addition of 1 mg of dexamethasone to syringe drivers can 
significantly extend the longevity of the subcutaneous infusion site22; 
• The use of Teflon® or Vialon® cannulas reduces site inflammation6, 8. 
One study from the UK suggests that 1500 units of hyaluronidase can be 
injected into the site prior to the infusion commencing if the skin is not 
already irritated.  Hyaluronidase acts to macerate the subcutaneous tissue, 
thereby increasing drug absorption9.  The injection only needs to be given 
once per site, not daily6.  Hyaluronidase usage is uncommon within Australia 
for subcutaneous drug administration, being more commonly used for more 
rapid subcutaneous fluid administration for rehydration. This low dose of 
hyaluronidase is also contraindicated in patients with asthma9.  
The longevity of the site can vary considerably from 1–14 days.  Many variables 
influence the longevity of the site, such as the type of medication and cannula/
needle used.  Rather than relying on a time-frame for resiting the infusion, the 
onset of a site reaction should dictate this practice9.  
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Site inspection:
Meticulous site inspection is integral to early identification and prevention of site 
related complications, and should be performed as part of routine care3, 7, 9.  Any 
site problems can potentially cause patient discomfort.  They also interfere 
with drug absorption and compromise effective symptom control.  When 
inspecting the site, check for:
•  Tenderness or hardness at the site;
• Presence of a haematoma;
• Leakage at the insertion site;
• Swelling—a sterile abscess can occur at the insertion site, causing local 
tissue irritation7;
• Erythema (redness);
• The presence of blood in the tubing;
• Displacement of the cannula11.
In addition to checking the site regularly (4 hourly is recommended), other 
important patient checks include:
• Asking the patient how they feel (or family member/carer, if the patient is 
unable to comprehend):  is their pain and other symptoms controlled? 
• Ensuring that the light on the syringe driver is flashing, and a ‘whirring’ 
sound can be heard as the device delivers the infusion;
• Checking the volume remaining in the syringe, and that the device is 
running to time;
• Ensuring there are no leakages, and that the connections to the syringe 
and the cannula are firm.
24
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Table 2:  Site preparation and insertion
The BD Saf-T-Intima® has a Vialon® cannula, which is one of the preferred 
cannulas when using a syringe driver in clinical practice11. 
 It is important to refer to the protocols for site preparation and insertion 
used within individual organisations.  
Principles for preparing the site and inserting the cannula include:
An aseptic technique must be employed, as many patients who 
require a syringe driver are immuno-compromised.  Ensure hands are 
washed thoroughly7.
In consultation with the patient and family, select a suitable site7. 
Choose the site using the guidelines (see preferred sites).  
Select and use sites on a rotating basis2.
Prepare the skin using an alcohol swab, and wait for skin to dry.
The point of the cannula should be inserted just beneath the 
epidermis.  For thin people the angle of the cannula on insertion may 
need to be less (30 degrees) than for a person with more subcutaneous 
tissue (45 degrees).  A deeper infusion may  prolong the life of the 
infusion site.
To insert:  
Grasp the skin firmly to elevate the subcutaneous tissue.  Insert the 
cannula and release the skin.
Remove the stylet if using a BD Saf-T-Intima® and take care to hold 
the device in situ when removing the stylet so that the entire device 
is not accidentally removed from the patient.
•
•
•
•
•
•
•
25
Note:  If a BD Saf-T-Intima® is not being used, place the bevel of the 
metal device downwards to deliver the drugs more deeply into the 
skin, and minimise irritation.
The extension tubing is changed when the cannula is changed. 
When the tubing is placed against the skin, form a loop to prevent 
dislodgement if the tubing is accidentally pulled9.  Use a transparent, 
semi-occlusive dressing to cover the site, as this permits inspection of 
the site by the caregiver8, 9.
Connect the syringe to the syringe driver.
Record and document that the infusion has been commenced as per 
local drug administration policies.
•
•
•
•
•
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SECTION FOUR
Drugs and Diluents
Summary Statement
Drugs and diluents
Syringe drivers can be used to deliver drugs to treat a variety of symptoms.  
Common symptoms include pain, nausea, vomiting,  breathlessness, 
agitation, delirium and “noisy breathing”;
A wide variety of drugs can be used together in different combinations 
with no clinical evidence of loss of efficacy13;  
The more drugs that are mixed together, the greater the risk of 
precipitation and reduced efficacy9;  
2–3 drugs may be mixed in a syringe for a subcutaneous infusion 
(occasionally up to 4 drugs6, 10);  
If compatibility is an issue, the use of two syringe driver devices3 or 
regular or prn subcutaneous injection should be considered;
 Before mixing any drugs together in a subcutaneous infusion, check for 
stability information3, 6, 9 and check with hospital pharmacists; 
Use of the boost facility is not recommended because it rarely provides 
enough analgesia to cover uncontrolled pain, and if other drugs are 
being infused overdosing could occur of the other drug(s)6.   
It is better to use breakthrough medication to treat uncontrolled 
symptoms than the boost facility14; 
Normal saline is the most commonly used diluent in Australia15;
The use of water for injection has been linked to pain due to its 
hypotonicity, although normal saline may be more likely to cause 
precipitation16;
5% dextrose is used only occasionally as a diluent6, and is less commonly 
used in Australia8.  
•
•
•
•
•
•
•
•
•
•
•
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Drugs
Subcutaneous infusion of drugs is a commonly used method for delivering a 
wide range of medication, particularly when other drug routes are no longer 
available, or are unacceptable to the patient9. Pain is the most common 
symptom for which control is sought,  but the use of syringe driver devices is 
not limited to analgesic administration.  Drugs to control other symptoms, such 
as nausea, vomiting,  dyspnoea, agitation, delirium and terminal phase “noisy 
breathing” can also be prescribed for continuous subcutaneous infusions and 
administered in the same syringe2.
Commonly, two–three drugs and occasionally up to four drugs10 may be 
mixed in a syringe for a subcutaneous infusion.  The maximum number of 
drugs that most clinicians are prepared to mix in a single syringe is four5.  The 
more drugs that are mixed together, the greater the risk of precipitation and 
reduced efficacy9.  It has been reported that a wide variety of drugs can be 
used in different combinations with no clinical evidence of loss of efficacy13. 
If compatibility is an issue, the use of two syringe driver devices3  may 
be considered.
In the Australian context, symptoms that are encountered at the end of life are 
generally well controlled by the use of nine commonly used medications23.  
These include:
morphine sulphate/tartrate (an opioid); 
hydromorphone (Dilaudid, an opioid);  
haloperidol (Serenace, an antipsychotic/antiemetic); 
midazolam (Hypnovel, a short acting benzodiazepine); 
metoclopramide (Maxolon, an antiemetic);
hyoscine hydrobromide (Hyoscine, an antimuscarinic /antiemetic);
clonazepam (Rivotril) – a benzodiazepine;
hyoscine butylbromide (Buscopan, an antimuscarinic); and
fentanyl (a narcotic).
•
•
•
•
•
•
•
•
•
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An important safety consideration, before mixing any drugs together in a 
subcutaneous infusion, is to check for stability information3, 6, 9.  Check with 
hospital pharmacists to confirm information or clarify any questions regarding 
stability.  Temperature may affect the stability of drugs.  This can be overcome 
by ensuring the syringe driver device is placed on top of bed clothes and 
outside of clothing, rather than beneath them6.  
Medications contraindicated for use in syringe drivers: 
Drugs such as prochlorperazine (an antiemetic), diazepam (an anxiolytic) 
and chlorpromazine (an antipsychotic) are specifically contraindicated 
for use in subcutaneous infusions due to severe localised reactions9,16. 
There are several drugs that have also been linked to abscess formation 
when used in subcutaneous infusions.  These include pethidine (pethidine 
hydrochloride—an analgesic), prochlorperazine (Stemetil—an antiemetic) 
and chlorpromazine (Largactil—an antipsychotic)11. 
Diluents
The choice between water for injection and 0.9% saline (normal saline) as a 
diluent is a matter of debate. The literature is divided with some recommending 
water for injection as the  diluent6, 8, 9, 15, and recent literature recommending 
normal saline11 as the diluent.  Normal saline can be used for most drugs, the 
main exception being cyclizine6. 
Normal saline is most commonly used within Australia for two reasons11: 
Firstly, the majority of drugs can be diluted with normal saline with only 
two exceptions: cyclizine and diamorphine (neither of which are commonly 
used in Australia);
Secondly, normal saline is isotonic, as are most injectable formulations. 
By diluting with normal saline, the tonicity of the solution is unaltered. 
Water for injection is hypotonic.  Using this as a diluent will potentially 
produce a hypotonic solution.  The literature suggests that hypotonicity 
can contribute to the development of site reactions11. For example, the 
use of water for injection has been linked to pain due to its hypotonicity, 
although normal saline is more likely to cause precipitation16.
There is a need for ambiguities to be addressed by further research, given the 
lack of clinical evidence or recommendations regarding diluents15.
•
•
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SECTION FIVE
Patient/family education needs
Summary Statement
Patient/family education needs
Patient and family education promotes safety and acceptance of the 
syringe driver as a means to providing improved symptom control12;
Patient and family education includes:
Explanation and education about what the device will do, and its 
advantages and possible disadvantages;
Safety aspects;
Ways to incorporate a subcutaneous infusion into their everyday life;
Troubleshooting guidelines9.
Careful explanation and education about what the device will do, and its 
advantages and possible disadvantages is required8. Patient and family 
education guidelines are outlined in Table 3.
•
•
•
•
•
•
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Table 3:  Patient and family education
Information about the 
device itself
Syringe driver devices are very reliable.
It is normal for the syringe driver to make 
a “whirring” noise every few minutes.  It 
should not be loud enough for others to 
hear or to keep them awake at night.
It is normal for a green light to flash on 
the right hand side of the machine.  If 
this light stops, the battery needs to be 
changed.  Instruct the patient that it is a 
good idea to keep a spare 9 volt battery. 
Encourage the patient to get into the 
habit of checking that the light is flashing 
and the “whirring” sound is coming from 
the machine,  but encourage them not to 
worry about checking it overnight.
The machine has an alarm which is a 
constant piercing sound.  Eventually 
the alarm will turn itself off.  Instruct the 
patient not to panic if it alarms.  It will 
alarm if the syringe is empty, or there is a 
blockage in the tubing.
•
•
•
•
•
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Activities of daily living
Carrying the 
syringe driver
Purchasing a belt bag to conceal and carry the 
device discreetly may be useful.
Showering The syringe driver must not be immersed in 
water and can be damaged by steam.
Although it is possible to disconnect the driver 
for a short duration, disconnection from the 
syringe driver is not encouraged.
If disconnection does occur: 
The patient does not need to turn off the 
syringe driver. It is important to inform the 
patient that they are unlikely to be affected 
in terms of worsening symptoms for the brief 
period that the syringe is disconnected from 
the device, but should also be informed that 
they will not receive any medication from the 
syringe driver while it is disconnected.
Once the syringe is replaced into the syringe 
driver the patient or family will need to 
press the start/boost button to recommence 
the infusion.
•
•
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Extra pain or 
breakthrough 
of unrelieved 
symptoms 
The patient may require reassurance that 
although they may continue to experience some 
pain, breakthrough medication can be given on 
these occasions14.
(*Breakthrough medication is defined as extra 
medication that may be required for symptoms 
that are not controlled by the medications 
prescribed for continuous delivery via the 
syringe driver).
Troubleshooting If the patient is concerned that the device is not 
functioning properly, the following guidelines 
for patient and family can assist:
If the patient believes there is something 
wrong with the syringe driver, or if the alarm 
sounds, reassure them that it is likely to be an 
easy problem to rectify.
Check that the light on the right hand side of 
the device is flashing.  If not, change the battery 
and press the button labelled “start/boost” and 
the light should begin to flash.
If the alarm is sounding, take out the battery as 
that is the only way to stop the noise.
Check:
If there is a kink in the tube - untwist it.
If the syringe is disconnected from the machine, 
attach it again with the black strap.  Replace 
the battery and press the “start” button.
If the syringe is empty or the cannula has come 
out, if the cannula site is swollen, or if there is 
pain at the site of the cannula,  the patient will 
need to contact their healthcare provider.
•
•
•
•
•
•
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SECTION SIX
Patient assessment and troubleshooting guidelines
Summary Statement
Patient assessment and troubleshooting guidelines
When troubleshooting the equipment used in subcutaneous infusions, it 
is important to understand the normal functioning of the device9;
Ensure that drug calculations are checked according to legislative 
requirements and organisational policy and protocols when the syringe 
driver is set up;
Use only one type of syringe driver in each setting to prevent confusion 
which may lead to errors6, 8, 10, 18;
Ensure that the organisational protocol is followed regarding priming of 
the line2, 6-9;
Ensure that drugs being delivered are compatible3, 19;
Ensure that a spare 9 volt battery is always available5, 6, 8;
Thorough patient assessment is important when caring for patients with 
a subcutaneous infusion7, 12;
Principles to include in patient assessment recording and documentation 
include:
Careful inspection of site, at least 4 hourly, for signs of inflammation 
and site reaction, then documentation of findings17;
Careful inspection of syringe volume remaining6, at least 4 hourly, and 
documentation of findings;
Ask the patient how they feel (or family member/carer, if the patient 
is unable to comprehend):  for example, are their pain and other 
symptoms controlled?;
Document symptom control and efficacy of interventions;
Careful inspection of tubing for patency8, 9 at least 4 hourly and 
documentation of findings;
•
•
•
•
•
•
•
•
•
•
•
•
•
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Site inspection should be performed as part of routine care and 
includes principles such as checking for: tenderness at the site; 
presence of a haematoma and leaking at the insertion site3, 7, 9.
Section Six of the guidelines addresses patient assessment and trouble- 
shooting.  When troubleshooting any equipment, it is important to understand 
the normal functioning of the device.  
These principles include ensuring that:
There is an intermittent ‘whirring’ sound;
There is a flashing light which indicates that the syringe driver is functional.
Patient assessment recommendations are presented in Table 4.  A comprehen-
sive troubleshooting guideline is presented in Table 5.
Management Guidelines
Table 4:  Patient Assessment guidelines
Potential problem Reducing potential problems
1) Site inflammation, infection 
and/or abscess development
Carefully inspect site, at least 4 
hourly and document findings.
•
2) Precipitation/crystallising 
in tubing
Ensure that the drugs being 
delivered are compatible19;
Carefully inspect tubing, at 
least 4 hourly, and document 
findings.
•
•
3) Disconnection of tubing Use Luer-Lock® syringes;
Carefully inspect tubing, at 
least 4 hourly, and document 
findings.
•
•
•
•
•
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4) Inappropriate dosages being 
delivered due to:
Confusion over the type 
of syringe driver device
Device running too fast/ 
too slow
Incorrect setting or 
setting moved
Confusing millimetres 
with millilitres
Different policies/practices 
regarding priming of the line 
•
•
•
•
•
Ensure only one type of syringe 
driver is used in each setting to 
prevent confusion;
Always measure the syringe each 
time the device is set up.
Carefully inspect infusion and 
syringe volume,  at least 4 hourly, 
and document findings.
Carefully inspect the syringe 
volume remaining, at least 4 
hourly,  and document findings.
Ensure only one type of syringe 
driver is used in each setting to 
prevent confusion.
Ensure that organisational 
protocol is followed regarding 
priming of the line (refer 
to Section One of these 
guidelines).
•
•
•
•
•
•
5) Calculation errors Ensure that all drug calculations 
are checked according to 
legislative requirements and 
organisational policy and 
protocols when the syringe 
driver is set up.
•
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6) Tampering with boost 
button facility or 
syringe driver settings
Consider using a tamper-
proof ‘lock-box’6 if there is a 
possibility of the patient or oth-
ers tampering with the device, 
or using the boost facility.
•
7) Battery running flat Ensure that a spare 9 volt battery 
is always available;
Ensure that the light is flashing 
on the syringe driver.
•
•
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Table 5:  Troubleshooting
Clinical 
situation
Possible cause(s) Suggested solution(s)
Pump 
alarms (long, 
continual 
‘beep’ which 
will stop after 
a while)
The syringe may 
be empty;
Tubing is kinked, 
needle is blocked, 
plunger is jammed;
Battery is flat.
•
•
•
Re-fill syringe;
Un-kink tubing;  
check plunger is 
not sticking;
Change battery.
•
•
•
Infusion
has not 
run to time
Rate set incorrectly, 
or has been altered;
Scale length 
measured 
incorrectly;
Pump has been 
immersed in water.
•
•
•
Set correct rate—
consider tamper-
proof box;
Re-measure 
syringe—check 
measurement;
Instruct that pump 
should not be 
immersed.
•
•
•
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Infusion 
has ended 
too early
Boost button 
may have been 
activated;
Rate could be set 
incorrectly, or it has 
been altered;
Check the scale 
length has been 
measured correctly.
•
•
•
Consider using 
a tamper-proof 
‘lock-box’6 if there is 
a possibility of the 
patient or others 
tampering with the 
device, or using the 
boost facility;
If rate has been 
incorrectly set, 
recalculate;
Remeasure the 
scale length to 
ensure accuracy.
•
•
•
Infusion has 
yet to be 
completed
Pump has been 
stopped;
 
Actuator may not 
have been flush 
against the plunger 
when infusion 
commenced;
Scale length 
measured 
incorrectly;
Rate setting is 
incorrect.
•
•
•
•
Check why the 
pump may have 
stopped. Flat 
battery?  Syringe 
empty?  Occlusion? 
– implement 
corrective action;
Check actuator is 
flush against the 
plunger;
Remeasure scale 
length to ensure 
accuracy;
Repeat rate 
calculation.
•
•
•
•
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Clinical 
situation
Possible cause(s) Suggested solution(s)
The infusion 
has stopped 
(i.e. the light 
is not
flashing)
Infusion has finished;
Line is blocked, or 
cannula is blocked; 
Possible battery 
problem;
Drugs have 
precipitated;
Inflammation 
at the site;
Syringe incorrectly 
fitted;
Mechanical 
malfunction.
•
•
•
•
•
•
•
Reload syringe as per 
medical order.
Check extension set 
not kinked, or clamp in 
place.
Check battery is 
inserted correctly;
If battery is flat, change;
Check START button 
not depressed 
sufficiently. 
If the drugs precipitate 
(crystallise)  in the 
syringe, discard the 
mixture. To prevent 
this happening again, 
you could increase the 
dilution, change the 
syringe line and re-site 
the cannula. If drugs 
mixed in the syringe 
precipitate, check their 
compatibility. The 
medication regimen 
may need to be simpli-
fied, or two pumps 
used7.
Change site; 
Continue to observe 
site for resolution of 
inflammation. 
Recheck set-up of 
driver.
Send for maintenance.
•
•
•
•
•
•
•
•
•
•
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Clinical 
situation
Possible cause(s) Suggested solution(s)
Limited 
cannula 
access 
sites
Oedema/ infection 
or patient may be 
cachectic.
• Confer with 
experienced 
colleagues;
Consider if a 
subcutaneous 
infusion is 
appropriate;
Refer to ‘site selection’ 
area of these 
guidelines.
•
•
•
Patient is 
restless 
and/or 
confused
Delirium (reversible) 
see Australian 
Medicines Handbook 
‘Drug Choice 
Companion: Aged 
Care’ 2003 pp 9-12 
(http://www.amh.net.
au);
Possibility of terminal 
delirium; 
Pain—check bladder, 
bowel etc.
•
•
•
Treat the underlying 
cause as appropriate.
Consider re-siting 
the cannula around 
the scapula;
Consider giving a 
breakthrough dose 
of an antipsychotic 
agent such as 
haloperidol11.
Check if the bladder 
is full, and implement 
appropriate 
management 
strategies, eg. insert 
an IDC if necessary.
•
•
•
•
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Clinical 
situation
Possible cause(s) Suggested solution(s)
Cannula 
site 
inflamed 
after only 
24-48 
hours
Skin reaction 
at the site;
Patient has 
had previous 
radiotherapy 
to the site;
High drug 
concentration in 
syringe causing 
irritation;
The site is infected;
Syringe contains 
drugs not 
appropriate for 
subcutaneous 
infusions;
Shallow cannula 
insertion.
•
•
•
•
•
•
Resite the needle, 
and observe for 
abscess formation.
Resite to area not 
previously treated. 
Dilute the 
concentration using 
a larger syringe -  
i.e. change from 10  
to 20/30ml syringe.
Remove cannula, and 
observe for clinical 
signs of infection
 Ensure that drugs 
are suitable for the 
subcutaneous route;
Adding 1mg of 
dexamethasone 
to the syringe may 
reduce site irritation.
Remove and resite 
the cannula, and 
observe the old site 
for signs of infection. 
•
•
•
•
•
•
•
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Clinical 
situation
Possible cause(s) Suggested solution(s)
The patient 
experiences 
pain at the 
insertion 
site
Shallow cannula 
insertion;
Inflammation.
•
•
Remove and resite 
cannula;
See previous page.
•
•
Leakage 
at the 
insertion 
site
Cannula position is 
not stable.
• Remove and resite 
cannula.
•
Bleeding 
at the 
insertion 
site
Trauma or 
coagulation problem.
• Remove cannula and 
apply pressure at old 
site;  when resited, 
observe site for 
further bleeding.
•
Patient 
reports 
unrelieved 
pain and 
control of 
symptoms
Leakage from the 
device;
Therapeutic dose has 
not been achieved 
in serum levels 
>24 hours after 
commencement of 
infusion.
•
•
Ensure syringe 
connections are 
secure—use 
Luer Lock® device;
Check all 
connections, 
changing 
components as 
necessary.
Consult medical 
staff to review 
medications;
Give available 
breakthrough 
doses until optimal 
symptom control is 
achieved.
•
•
•
•
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Clinical 
situation
Possible cause(s) Suggested solution(s)
Patient 
reports 
unrelieved 
pain 
and/or 
poor 
control of 
symptoms
Medication order is 
inappropriate;
 Inappropriate 
dose of medication 
prepared.
•
•
Assess the patient, 
confer with medical 
staff to adjust 
dosage.
Recheck the 
medication order, 
and draw up the 
correct dose;
Complete an incident 
form and notify the 
correct persons.
•
•
•
Please note:  If any of the above cannot be explained, the device may be faulty 
and should be checked by a medical engineer. 
Conclusion
 
The use of syringe drivers in palliative care to achieve symptom control is 
standard and accepted practice.  There are many benefits that syringe drivers 
present to the patient in terms of convenience and effective management 
of symptoms. However use of this device has not been without its risks and 
limitations, including the inflexibility of prescription, technical problems, 
safety issues and skin reactions at the site of the infusion.  
Syringe drivers may also cause concerns and fears for some patients and their 
families because they are associated with disease progression.  
The guidelines presented in this report are intended to promote a standardised 
approach to clinical care, thereby minimising practice errors that can result in 
serious adverse events that present an on-going risk for patient safety.
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Appendix A - Levels of Evidence1
Level of Evidence Effectiveness
1 Systematic Review (with homogeneity) of Experimental 
studies (eg.  Randomised Control Trial with concealed 
allocation); 
Or 1 or more large experimental studies with narrow 
confidence intervals.
•
•
2 Quasi-experimental studies (eg. without randomisation).
3 3a. Cohort studies (with control group);
3b. Case-controlled; 
3c Observational studies without control groups.
4 Expert opinion without explicit critical appraisal, or based 
on physiology, bench research or consensus.
1. Joanna Briggs Institute. Levels of Evidence. Joanna Briggs Institute. Available at <http://www.
joannabriggs.edu.au/pubs/best_practice.php>. Accessed April 18th, 2005.
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Appendix B - Literature Summary
Level of
Evidence
Sample
(if 
applic)
Setting Aims Design Methods Results
British National Formulary.  ‘Syringe drivers.’ <www.bnf.org>. Accessed 26th January, 2005.
4 N/A N/A N/A British 
National 
Formulary 
website
N/A N/A
Coleridge-Smith E. The use of syringe drivers & Hickman lines in the community.
British Journal of Community Nursing 1997;2(6):292, 294, 296.
3 N/A N/A N/A Evidence 
based 
guidelines
N/A N/A
Dickman A, Littlewood C, Varga J. The Syringe Driver. Oxford: Oxford University Press; 2002.
3 N/A N/A N/A Reference 
book about 
syringe 
drivers
N/A N/A
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Level of 
Evidence 
Sample
(if 
applic)
Setting Aims Design Methods Results
Dunne K, Garvey A, Kernohan G, Diamond A, Duffy C, Hutchinson J. An audit of
subcutaneous syringe drivers in a non-specialist hospital.
International Journal of Palliative Nursing 2000;6(5):214, 216-219.
3 13 cases of
palliative 
care
patients
Not
specified
To establish 
the standard 
of current 
practice in 
wards where 
syringe 
drivers were 
being used.
Clinical audit 
(retrospec-
tive study)
Clinical 
audit 
methods.
Highlighted 
many areas of 
unregulated 
practice with
regard to 
setting up, 
monitoring & 
maintenance 
of syringe 
drivers. 
Flowers C, McLeod F. Diluent choice for subcutaneous infusion: a survey of the literature
and Australian practice. International Journal of Palliative Nursing 2005;11(2):54-60.
3 N/A Australian 
practice set-
tings (and 
national and 
internation-
al literature 
search). 
To deter-
mine dilu-
ent choice 
for subcu-
taneous 
infusions in 
the litera-
ture and in 
Australian 
practice.
Survey of 
clinical 
practice 
settings; 
literature 
search.
Literature 
review 
considered 
existing  
literature, 
drug 
databases & 
directories;
involved a 
survey of 
palliative 
care services 
to examine 
evidence & 
experience 
relating 
to diluent 
choice.
With the
exception of 
five drugs for 
which saline 
was recom-
mended, there 
was an  
inclination 
to use water 
unless contra-
indicated.
More research 
is needed 
to address 
formal clinical 
evidence & 
ambiguities.
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Level of 
Evidence 
Sample
(if 
applic)
Setting Aims Design Methods Results
Gomez Y. The use of syringe drivers in palliative care.
Australian Nursing Journal 2000;(2):suppl 1-3.
3 N/A N/A Outlines 
application 
of syringe 
drivers, in 
particular 
the Graseby 
MS16A in a  
palliative 
care 
setting
Evidence 
based 
instruction 
guide
N/A N/A
Hayes A, Brumley D, Habeggar L., Wade M, Fisher J, Ashby M. 
Evaluation of training on the use of Graseby syringe drivers for rural non-
specialist nurses. International Journal of Palliative Nursing 2005;11(2):84-92.
3 270 non-
specialist 
nurses
Rural
Grampians 
Health 
Region in 
Victoria, 
Australia
To assess the 
impact of a
training 
programme 
on nurse 
confidence 
in setting 
up, and  
explaining 
the Graseby 
syringe 
driver
Training 
program
Pre-training 
post-
training and 
follow up 
question-
naires
Increases in 
confidence 
levels were 
found in 
participating 
nurses in  
relation 
to each of 
the four 
confidence 
parameters
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Level of 
Evidence 
Sample
(if 
applic)
Setting Aims Design Methods Results
Lichter I, Hunt E. Drug combinations in syringe drivers.
The New Zealand Medical Journal 1995;108(1001):224-226.
2 One 
hundred
consecutive 
patients in 
a palliative 
care
setting
New
Zealand
To record 
the combi-
nations of 
drugs in SD’s 
that were 
found to be 
compatible
Experimental Case series.
Because 
of widely 
differing views 
on the drugs 
that can be 
administered 
in combination, 
a study was 
undertaken 
to record the 
combination 
of drugs in 
syringe drivers 
that were 
found to be 
compatible. 
The content 
of syringe 
drivers in 100 
consecutive 
patients 
in whom 
continuous 
subcutaneous 
infusion was 
used, was 
recorded. The 
incidence of 
skin reactions 
with the 
different drugs 
was noted. 
The efficacy of 
combinations 
used was 
assessed 
clinically
It was found in 
this study that 
a wide variety 
of drugs were 
used in many 
different 
combinations, 
with no clincal 
evidence of 
loss of efficacy. 
Some drug 
combinations 
were 
incompatible. 
Drugs known 
to cause skin 
reactions 
were not 
administered. 
In this study 
skin reactions 
depended on 
the number of 
drugs used in 
combination. 
The study 
concluded 
that the array 
of medications 
that can be 
used together 
in syringe 
drivers enable 
this method 
of drug 
administration 
to be used 
successfully 
in the control 
of the diverse 
symptoms 
that may arise 
in terminal 
illness
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Level of 
Evidence 
Sample
(if 
applic)
Setting Aims Design Methods Results
McNeilly P, Price J, McCloskey S. The use of syringe drivers: a pediatric perspective. 
International Journal of Palliative Nursing 2004;10(8):399-404.
3 N/A Examine 
specific
issues 
concerning 
the use of 
SD when 
caring for 
children 
and young 
people
N/A Evidence 
based 
guidelines
N/A N/A
McQuillan R, Finlay I. The utilization of syringe drivers at a teaching hospital.
Palliative Medicine 1996;10(1):52.
4 N/A University 
Hopital of 
Wales
Correspondence 
about utilisation of 
syringe drivers at a 
teaching hospital 
in Wales
Cor-
respon-
dence
N/A The most 
common types 
of syringe driver 
used in Britain 
are the Graseby 
MS16A and MS26 
machines; 
approx. 2500 of 
these are sold 
annually in the 
UK and a similar 
number sold 
abroad. The 
simple Graseby 
syringe drivers 
cost about 
£600 each; the 
manufacturer 
does not 
recommend 
routine 
maintenance. In 
theory a syringe 
driver could be 
in use 100% of 
the time, but 
because of loss 
and under-usage 
of syringe drivers, 
they are not used 
efficiently at 
some centres.
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Level of 
Evidence 
Sample
(if 
applic)
Setting Aims Design Methods Results
Mitten T. Subcutaneous drug infusions: a review of problems and solutions.
International Journal of Palliative Nursing 2001;7(2):75-85.
3 N/A N/A Reviews 
general issues 
with the 
operation of 
portable SD, 
& discusses 
a range of 
potential 
problems & 
solutions.
Evidence 
based 
guidelines
N/A N/A
Morgan S, Evans N. A small observational study of the longevity of syringe driver sites in 
palliative care. International Journal of Palliative Nursing 2004;10(8):405-412.
3 27 
Palliative 
Care 
patients 
examining 
86 syringe 
driver 
sites
UK hospice 
setting
To establish 
the rate of 
SD reactions, 
duration of 
sites and to 
determine 
whether a 
predictable 
relationship 
existed 
between the 
number of 
days on a SD 
and number 
of sites used 
consecutively.
Observa-
tional study
A proforma 
was 
designed 
to collect 
information.
Data 
collected 
included:
date and 
time of 
set-up; 
medication 
doses; date 
& time site 
discontinued; 
presence of 
site reaction; 
body site 
used.
44% 
discontinued 
due to site 
reactions; 
Location of SD 
site appeared to 
be an important 
factor; 
Dislodgement 
3 x more 
prevalent from 
chest wall than 
upper arm; 
Sites must 
be inspected 
regularly;
There is no 
evidence base 
- more research 
is needed.
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Level of 
Evidence
Sample
(if 
applic)
Setting Aims Design Methods Results
O’Doherty C, Hall E, Schofield L, Zeppetella G. Drugs and syringe drivers: 
a survey of adult specialist palliative care practice in the United Kingdom and Eire. 
Palliative Medicine 2001;15:149-154.
3 Palliative 
care 
specialists
UK The aim of the 
present study 
was to reassess 
practice in 
the field of SD 
management 
and to enquire 
more specifically 
about newer 
drugs.
Survey Survey methods The maximum 
number of drugs 
that respondents 
were prepared 
to mix in a single 
syringe was usually 
three (51%) or four 
(35%). In the UK, all 
units used 
diamorphine in 
doses from 2.5mg/
24h upwards. All 
respondents also 
used haloperidol, 
in doses from 0.5 
to 60mg/24 h.
A total of 28 
different drugs 
were used in 
syringe drivers. 
The most common 
combinations were 
diamorphine and 
midazolam (37%), 
diamorphine and 
levomepromazine 
(35%), diamorphine 
and haloperidol 
(33%), and 
diamorphine and 
cyclizine (31%).
Ratcliffe N. Syringe drivers. Community Nurse 1997;3(6):25-26.
4 N/A N/A N/A Instruc-
tion 
guide-
lines
N/A N/A
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Level of 
Evidence
Sample
(if 
applic)
Setting Aims Design Methods Results
Reymond L, Charles MA, Bowman J, Treston P.  The effect of dexamethasone on the longevity
of syringe driver subcutaneous sites in palliative care patients. MJA. 2003;178:486-489.
tti Design Methods Results
Reymond E, Charles M. An intervention to decrease medication errors in palliative patients 
requiring subcutaneous infusions: Brisbane South Palliative Care Service and Adverse Drug 
Event Prevention Program; unpublished report presented to Clinical Services Evaluation Unit, 
Princess Alexandra Hospital, Brisbane, Australia; 2005.
3 Seventy-
six 
palliative 
patients 
requiring 
subcu-
taneous 
infusions 
were 
involved; 
a total 
of 217 
syringe 
driver 
days
Hospital 
in South-
east Qld, 
Australia
To improve the 
standard of care 
for palliative 
patients 
with the 
implementation 
of a quality 
improvement 
intervention, 
namely a new 
subcutaneous 
infusion 
proforma, and 
to evaluate 
the outcome 
in terms of 
infusion errors 
and staff 
feedback.
Clinical 
audit
NUMs, from 
wards that 
manage 
palliative 
patients, 
nominated 60 
nurses interested 
in becoming 
“staff champions” 
for subcutaneous 
infusions. 25 
nominees 
attended one 
of five 3-hour 
workshops, 
facilitated by 
a specialist 
palliative care 
nurse, concerning 
education 
strategies for the 
administration 
and management 
of subcutaneous 
infusions 
incorporating the 
new proforma. 
After the 
workshops were 
completed the 
new proformas 
were introduced 
to the wards and 
all previously 
used forms 
removed. One 
month later 
the audit was 
repeated.
The most 
frequently 
occurring errors 
that compromised 
patient symptom 
control were 
those relating to 
operational checks. 
Pre-intervention 
this occurred 
due to the use of 
non-standardised 
forms, many of 
which did not 
prompt nursing 
staff to check 
subcutaneous 
infusions four 
hourly. According 
to feedback 
from staff, post-
intervention it 
occurred because 
the checking 
documentation is 
on the reverse of 
the new proforma. 
According to staff 
feedback, if four 
hourly operational 
checks were 
routine then the 
audited equipment 
malfunctions or 
errors would have 
been detected 
earlier.
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Reymond L, Charles MA, Bowman J, Treston P. The effect of dexamethasone on the longevity
of syringe driver subcutaneous sites in palliative care patients. MJA. 2003; 178:486-489.
1 38 
palliative 
care 
patients
Two Aus-
tralian 
inpatient 
units at 
two 
hospitals
To assess 
the effect of 
adding 1mg of 
dexamethasone 
to SD on the vi-
ability time of 
subcutaneous 
sites in palliative 
care patients.
Prospective, 
double-
blind 
randomised 
controlled 
trial
Patients 
received their 
daily infusion 
medication 
plus 1mg 
dexamethasone 
in 1ml saline 
through one 
sc test site, 
and other 
received their 
medications 
plus 1ml 
saline though 
symmetrically 
placed site 
(control site).
Of 38 
participants, 
20 did not 
complete as site 
broke down;
Remaining 18 
either partially 
completed, or 
fully completed. 
Test sites lasted 
3.6 days longer 
than control 
sites.
The addition 
of 1mg 
dexamethasone 
significantly 
extended the 
viability time of 
SC cannulations 
in palliative care 
patients.
Wilson V. Clinical guidelines for use of the MS26 daily rate syringe driver in the community. 
British Journal of Community Nursing 2000;5(4):162-168.
4 N/A N/A N/A Guidelines 
for use of 
the Graseby 
MS26 in the 
community.
N/A N/A
PalliativeDrugs.com. ‘Syringe drivers.’ <www.palliativedrugs.com>.
Accessed 25th January, 2005.
4 N/A N/A N/A Drugs used 
in palliative 
care website
N/A N/A
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Appendix C - Commonly Used Drugs in Syringe Drivers6, 8
DRUG INDICATION COMMON DOSAGE VOLUME
morphine 
sulphate/
tartrate
(tartrate is 
used rather 
than sulphate 
for larger 
doses as it is 
more soluble).
Opioid for pain control.  
Morphine is 2-3 times 
more potent when given 
parenterally  than oral 
morphine.  Morphine is 
physically compatible 
with the other drugs 
commonly used in 
syringe drivers.
There is no 
maximum dosage 
of morphine.  Usual 
starting dose is 
10-20 mg per 24 
hours, which can be 
increased if pain is 
uncontrolled.
(as sulphate) 
5mg/ml; 
10mg/ml; 15mg/ml; 
30mg/ml
(as tartrate)
120mg/1.5ml; 
400mg/5ml
hyoscine  
hydrobromide 
(Hyoscine)
Antimuscarinic useful 
for drying secretions 
(e.g. sialorrhea, drooling, 
death rattle), intestinal 
colic, inoperable bowel 
obstruction.
200-400 microgram 
SC stat
600-1200microgram 
per 24 hours.
400 microgram and 
600 microgram/ml
clonazepam 
(Rivotril) 
A benzodiazepine 
derivative with 
antiepileptic properties.  
Several indications in 
palliative care:  terminal 
agitation, anxiety, 
myoclonus, seizures, and 
neuropathic pain.
Usual dose is 1-4 mg 
per 24 hours.
1mg/ml
hydromor-
phone (Dilau-
did)
Opioid for pain 
control.  Often used 
when morphine is not 
effective, or tolerated, 
in an attempt to control 
symptoms. 
There is no 
maximum dosage 
of hydromorphone.  
Usual starting 
dose is 2-4 mg per 
24 hours, can be 
increased if pain 
uncontrolled.
2mg/ml;
10mg/ml as 1 & 5ml 
ampoules
haloperidol 
(Serenace)
An antipsychotic agent 
and antiemetic.  Used 
in low doses to control 
nausea and vomiting, 
and has minimal 
sedative properties at 
this dosage.  Higher 
doses may control 
agitation and confusion.
As an antiemetic, 
1.5–5 mg  over
24 hours. 
To control delirium 
associated agitation, 
5-20 mg over
24 hours. 
5mg/ml
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DRUG INDICATION COMMON DOSAGE VOLUME
midazolam 
(Hypnovel)
A short acting 
benzodiazepine, used to 
control seizures, anxiety 
and terminal agitation.   
Tolerance can develop 
and the dose may need 
to be increased.
5-60 mg over 24 
hours.
5mg/ml
metoclo-
pramide 
(Maxolon)
An antiemetic and 
gastro kinetic, indicated 
when nausea is 
associated with gastric/
bowel stasis. 
30 –120 mg over 24 
hours. Occasional 
extrapyramidal side 
effects. 
10mg/2ml
hyoscine 
butylbromide
(Buscopan)
An antimuscarinic  used 
mainly for the treatment 
of intestinal colic.  Often 
used to dry terminal 
secretions.  Not directly 
an antiemetic, but does 
reduce gastrointestinal 
secretions.
60-180 mg over 24 
hours. 
20mg/2ml
fentanyl An opioid for pain 
control.  Not commonly 
given in the community 
as not PBS listed.
600 mcg/24 hours 
in a subcutaneous 
infusion equivalent 
to a 25 mcg/hr 
fentanyl patch.
500 mcg in 10 ml
100 mcg in 2 ml  
50 mcg in 1 ml
* This appendix  is intended as a guide only23.  It is important to refer to Hospital guidelines and 
onsite Pharmacist support.  
Please refer to the Disclaimer on Pg 2. To determine drug incompatibilities, you should refer to 
your Pharmacy Manual, or refer to your onsite Pharmacist19.
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